Management of neuroendocrine tumors of unknown origin

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue 12, 2011, Pages 1397-1402

  Polish, Ariel ^a   Vergo, Maxwell T ^a   Agulnik, Mark ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Neuroendocrine tumors; Unknown origin; Unknown primary

Indexed keywords

EVEROLIMUS; OCTREOTIDE; SUNITINIB; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CARCINOID; COMPUTER ASSISTED TOMOGRAPHY; FAMILY HISTORY; FEASIBILITY STUDY; GASTRINOMA; GLUCAGONOMA; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INSULINOMA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; TREATMENT OUTCOME; VIPOMA;

EID: 83755178042     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0118     Document Type: Article

References (12)

1. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
2. Kulke HM, Clark OH, Benson AB III, et al. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine Tumors. Version 1, 2011. Available at: http://www.nccn.org/professionals/physician-gls/pdf/neuroendocrine.pdf. Accessed October 20, 2011.
3. Oien KA. Pathologic evaluation of unknown primary cancer. Semin Oncol 2009;36:8-37.
4. Spigel DR, Hainsworth JD, Greco FA. Neuroendocrine carcinoma of unknown primary site. Semin Oncol 2009;36:52-59.
5. Wang SC, Parekh JR, Zuraek MB, et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg 2010;145:276-280.
6. Rosch T, Lightdale CJ, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992;326:1721-1726.
7. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-4663.
8. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003;197:29-37. (Pubitemid 36759176)
9. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-513.
10. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523.
11. Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. J Clin Oncol 2011;29:934-943.
12. Hainsworth JD, Spigel DR, Litchy S, et al. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network study. J Clin Oncol 2006;24:3548-3554. (Pubitemid 46630525)